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Background: There is increasing evidence for the efficacy of the antifungal voriconazole, particularly in immunosuppression. We describe
our experience of using voriconazole in children with CF.
Methods: We performed a retrospective case note review of children with CF treated with voriconazole in a single centre over an 18 month
period.
Results: A total of 21 children aged 5 to 16 years (median 11.3) received voriconazole for between 1 and 50 (22) weeks. Voriconazole was
used as monotherapy in 2 children with recurrent allergic bronchopulmonary aspergillosis (ABPA); significant and sustained improvements
in clinical and serological parameters for up to 13 months were observed, without recourse to oral steroids. Voriconazole was used in
combination with an immunomodulatory agent in a further 11 children with ABPA, with significant improvement in pulmonary function and
serology. 8 children without ABPA but who had recurrent Aspergillus fumigatus isolates and increased symptoms also received voriconazole;
this group did not improve with treatment. Adverse effects occurred in 7 children (33%: photosensitivity reaction 3, nausea 2, rise in hepatic
enzymes 1, hair loss 1).
Conclusions: Voriconazole may be a useful adjunctive therapy for ABPA in CF. Voriconazole monotherapy appears to be an alternative
treatment strategy when oral corticosteroids may not be suitable.
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1. Introduction A consensus guideline on management of ABPA in CFAspergillus fumigatus is frequently isolated from respi-
ratory secretions of patients with CF [1]. Although simple
isolation is usually thought to be unimportant and not
treated, allergic bronchopulmonary aspergillosis (ABPA) is
a much more serious response to the fungus [2]. ABPA
occurs in approximately 10% of CF patients [3], and
involves IgG and IgE mediated hypersensitivity reactions
[4]. The typical presentation is with wheezing, new
pulmonary infiltrates, a rise in serum total IgE and specific
IgE to A. fumigatus, with a fall in pulmonary function.1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.019
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E-mail address: t.hilliard@imperial.ac.uk (T. Hilliard).has been published recently [4]. The mainstay of treatment
is oral corticosteroid therapy, but this may need to be
continued for several months and is associated with
significant adverse effects [5]. It may also be worth
attempting to reduce the burden of A. fumigatus in the
respiratory tract [6]. Studies of itraconazole, initially in an
uncontrolled setting in CF [7,8], and recently in randomised
trials in adults with asthma and ABPA [9,10] have shown
evidence of benefit, including the ability to reduce steroid
dosage.
Voriconazole is a recently introduced triazole antifungal
with superior oral bioavailability to itraconazole which has
been approved for the treatment of invasive aspergillosis
[11]. It is however expensive, has a high potential for drug
interactions and has been associated with a number of
adverse effects [11]. We began using voriconazole as an4 (2005) 215 – 220ed by Elsevier B.V. All rights reserved.
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with CF in 2002. The decision to start voriconazole was
made by individual physicians with the following indica-
tions: (i) in ABPA as adjunctive therapy to immunomodu-
latory agents and a second-line antifungal therapy after
itraconazole, (ii) in ABPA as monotherapy where oral
corticosteroids were deemed unsuitable and (iii) for
increased respiratory symptoms with multiple positive
cultures for A. fumigatus, without serological evidence for
ABPA. We describe our experience in these three groups of
children, and in particular highlight the cases of two
children with ABPA in whom voriconazole therapy alone
appeared to be beneficial.2. Methods
We performed a retrospective case note review of all
children with CF who had received voriconazole between
October 2002 and March 2004 in a tertiary paediatric CF
centre with a clinic population of 350 children. Children
were identified from pharmacy records and clinical and
serological data were collected from case notes and
computerised laboratory records by a single investigator
(TH). All children had been reviewed on at least a 2
monthly basis at our centre. Microbiological data from the
12 months prior to starting voriconazole were recorded. For
children receiving voriconazole at the time of this review,
the most recent available data were included in the overall
analysis. For children who had received 2 courses of
voriconazole, parameters at the end of the second course
were recorded. Statistical analysis was performed with
Minitab13.1 (Minitab Inc, State College, PA, USA).
Wilcoxon signed ranks test was used to compare paired
data at the beginning and end of the treatment periods. A p
value of less than 0.05 was considered statistically
significant.3. Results
21 children received voriconazole over the 18 month
period to March 2004 (Table 1). 15 girls and 6 boys, median
age 11.3 years (range 5 to 16), were treated for a median of
22 weeks (1 to 50). The overall median FEV1 (% predicted)
at the time of starting therapy was 56% (29 to 88). The dose
of voriconazole was as recommended by the manufacturer’s
summary product characteristics. Children under 12 years of
age received 6 mg/kg (maximum 200 mg) twice a day (BD)
for 1 day and then 4 mg/kg (maximum 100 mg) BD. Those
over 12 years and less than 40 kg received 200 mg BD for 1
day and then 100 mg BD; if over 12 years and more than 40
kg, they received 400 mg BD for 1 day and then 200 mg
BD. 3 children are still on voriconazole at the time of
writing and 3 received 2 courses of treatment. If used
alongside a tapering course of oral corticosteroids, vorico-nazole was generally given for at least month after stopping
the steroids. No child received intravenous voriconazole.
We did not determine the blood concentration of voricona-
zole in any patient.
3.1. Children with ABPA
13 children had evidence of ABPA according to current
diagnostic criteria [4] (clinical deterioration, a rise in total
serum IgE to greater than 500 IU/ml and presence of both
IgE and IgG antibody to A. fumigatus), at the time of
starting voriconazole. Two children were given voricona-
zole as a single agent against ABPA and they are described
in detail below (Cases 1 and 2). Nine children were also
treated with oral corticosteroids and a further 2 children had
alternative immunomodulatory therapy (methotrexate in one
and monthly infusions of intravenous immunogobulin in the
other). Oral corticosteroids were given at an initial dose of 2
mg/kg per day of prednisolone (maximum 40 mg) for up to
2 weeks, followed by 1 mg/kg for the same period, before
changing to alternate day therapy. Weaning was guided by
the clinical response over the following weeks.
11 children had previous episodes of ABPA, and 9 had
isolated A. fumigatus on sputum or cough swab samples in
the previous year. All 11 with previous ABPA had been
treated with itraconazole during these episodes, and 3 were
switched from itraconazole to voriconazole during therapy
for this exacerbation. Both children without previous
ABPA had been started on itraconazole prior to starting
voriconazole.
All but 1 of these children also received inhaled
corticosteroids (equivalent median dose of budesonide of
1000 mcg per day, range from 200 to 2000), but the dose did
not change during treatment with voriconazole.
In this group as a whole, pulmonary function increased
significantly over the period of treatment with voriconazole;
FEV1 by a median of 13.5% (95% CI 2.5–24.5; p =0.01),
and FVC by 18.5% (95% CI 6.5–32; p =0.007). Total
serum IgE fell from a median of 1898 to 854 IU/ml (median
difference 887, 95% CI 389–1466; p =0.003).
3.2. Case 1
A 13 year old girl with CF presented with an increase in
cough and wheeze, a fall in FEV1 to 53% and FVC to 56%
(from 64% and 83% respectively). There were new bilateral
lower lobe infiltrates on chest radiography. She had
experienced 2 previous episodes of acute ABPA in the
preceding 2 years and had been given prolonged courses of
oral prednisolone with good recovery. Despite treatment
with intravenous antibiotics, her pulmonary function did not
improve, and a recurrence of ABPA was diagnosed on
clinical and serological grounds: total serum IgE 2089 IU/
ml (previously 482), specific IgE on RAST against A.
fumigatus 15.4 IU/ml. She refused oral corticosteroids on
this occasion as she had gained significant weight with prior
Table 1
Patient characteristics
No Age
(years)
Genotype ABPA
past
ABPA
active
AF1 PA2 SA3 Oral
steroids
Dose of
voriconazole
(mg)4
Weeks of
therapy
ICS
(mcg/day)6
RAST
IgE
(IU/ml)
IgE on
starting
(IU/ml)
IgE at
end
(IU/ml)
FEV1
(%) on
starting
FEV1
(%) at
end
Adverse effects Comments
Patients with ABPA
1 12.8 DF508/DF508 Y Y Y N N N 100 41 2000 15.4 2089 999 53 75 No 2 courses
2 16.2 DF508/DF508 Y Y N N Y N 200 325 1000 65.0 2162 860 71 80 No
3 12.2 DF508/DF508 Y Y Y Y N N 100 505 400 18.3 1138 601 42 58 Nausea and
headache
(stopped 1st course)
On methotrexate,
2 courses
4 13.8 DF508/DF508 Y Y Y N N N 200 215 800 18.6 1748 673 65 91 Photosensitivity
(Stopped 1st course)
On IVIG7,
2 courses
5 5.4 DF508/DF508 N Y N Y Y Y 100 36 800 16.9 1477 63 82 87 No
6 15.7 DF508/DF508 Y Y Y Y Y Y 200 19 800 31.5 2346 489 56 101 No
7 9.8 DF508/DF508 Y Y Y Y N Y 100 24 2000 18.8 536 166 70 87 Liver dysfunction
(stopped)
8 9.2 DF508/DF508 Y Y Y Y Y Y 100 1 1600 23.0 1898 2306 29 29 Nausea (stopped)
9 12.5 / Y Y Y Y Y Y 100 12 1600 10.7 607 367 66 98 No
10 12.6 DF508/DF508 N Y Y Y Y Y 200 26 800 59.3 4428 957 72 70 No Developed
IDDM8
on prednisolone
11 7.3 DF508/G542X Y Y N Y N Y 100 22 2000 101.0 8922 9036 88 80 No
12 12.9 DF508/DF508 Y Y Y Y N Y 100 33 2000 47.9 2684 1879 67 55 No
13 8.4 DF508/DF508 Y Y N Y Y Y 100 15 0 37.1 1823 854 44 73 No
Median 12.5 Y=11 Y=13 Y=9 Y=10 Y=7 Y=9 100 24 1000 23.0 1898 854 66 80 Y=4
Patients without ABPA
14 10.2 G551D/ N N Y N Y Y 100 22 200 10.8 417 – 56 51 No
15 13.4 DF508/DF508 Y N Y Y N Y 100 7 800 0.3 57 49 37 53 Hair loss (stopped) On alternate day
prednisolone
16 11.3 DF508/DF508 Y N Y N Y Y 200 29 800 2.0 268 126 62 43 Photosensitivity On alternate day
prednisolone
17 10.8 DF508/G542X N N Y Y N Y 100 2 1000 7.4 176 267 47 50 No
18 9.2 DF508/DF508 N N N N N Y 100 21 1600 1.0 30 98 41 56 No
19 10.9 DF508/DF508 N N Y Y N N 100 10 0 0.3 8 8 62 63 Photosensitivity
20 7.5 DF508/R553X Y N N N N N 100 28 400 1.7 209 236 43 64 No
21 14.8 / N N Y N Y N 200 4 800 0.3 36 40 54 48 No
Median 10.9 Y=3 Y=0 Y=6 Y=3 Y=3 Y=5 100 16 800 1.4 117 98 51 52 Y=3
Culture of 1Aspergillus fumigatus, 2Pseudomonas aeruginosa and 3Staphylococcus aureus in the preceding 12 months.
4twice per day.
5patient still receiving voriconazole therapy.
6inhaled corticosteroids, total budesonide dose per day or equivalent.
7intravenous immunogobulin.
8insulin dependent diabetes mellitus.
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of voriconazole as monotherapy with clinical and serolog-
ical improvement at the end of this period (FEV1 increased
by 11% to 64%, and total IgE fell to 1468). 2 months later
she became more symptomatic and her FEV1 had dropped
to 58%. Voriconazole was restarted and she had a sustained
improvement in her status over a further 8 month treatment
period (at the end of therapy FEV1 was 75% and total IgE
874). Changes in FEV1 and total IgE, over this 3 year
period, including the 13 months since starting voriconazole,
are shown in Fig. 1. Periods of treatment with intravenous
antibiotics are also marked.
3.3. Case 2
A 16 year old boy with CF reported rapidly increasing
cough and breathlessness. A chest radiograph showed a new
large round opacification in the left lower lobe as well as
bilateral lower lobe infiltrates. FEV1 had fallen from 77 to
71% (FVC 96 to 87%). Sputum over the previous year had
grown multiple isolates of Stenotrophomonas maltophilia
and Staphylococcus aureus but not A. fumigatus. He had
had 3 previous episodes of ABPA over the preceding 4 years
that had been treated with oral prednisolone and itracona-
zole. A recurrence of ABPAwas diagnosed (total serum IgE
2162 IU/ml, specific IgE to A. fumigatus 65 IU/ml). He
refused oral corticosteroids because of cessation of growth
during previous tapered courses. He was therefore given a
trial of voriconazole as monotherapy. He has now remained
on therapy for 7 months with a sustained clinical and0
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Fig. 1. Change in serum total IgE and FEV1 (% predicted) during periods of theserological improvement (FEV1 currently 80% and total IgE
has fallen to 860 IU/ml) without any recourse to oral
corticosteroids.
3.4. Children without ABPA
Eight children did not have evidence of active ABPA at
the time of starting voriconazole. Six of these had grown A.
fumigatus in the previous year. Of the other 2 children, one
had had previous ABPA, and the other was admitted with
severe acute wheezing which did not respond rapidly to oral
corticosteroids. All had a recent clinical deterioration, which
had failed to respond to conventional therapy, including
multiple courses of oral and/or intravenous antibiotics. A.
fumigatus was thought to be at least partly responsible for
their deterioration. 2 children were given voriconazole
without the prior use of itraconazole, and 5 were given
concomitant oral corticosteroids. In this group pulmonary
function did not change significantly (median FEV1
increased by 2% ( p =0.31), and forced vital capacity
(FVC) increased by 6.5% ( p =0.42)).
3.5. Adverse effects
Seven children (33%) experienced adverse affects
attributed to voriconazole. Three children (14%) had a
photosensitivity skin reaction, and in one this prompted
withdrawal of medication, although the drug was subse-
quently tolerated without any reaction in a second course.
Another child had persistent erthyema of sun-exposed areas,40
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rapy with voriconazole, oral steroids and intravenous antibiotics in case 1.
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at the time of taking the drug with ciprofloxacin, despite
taking the usual precautions against sun exposure. Two
children (10%) complained of nausea and/or headaches,
which led to cessation of therapy in both, although a second
course was subsequently tolerated by one of these. One
child had pre-existing CF related liver disease; voriconazole
therapy was stopped following deterioration in his liver
function tests after 5 months of treatment. One child had
hair loss and therapy was stopped. Overall, therapy was
discontinued due to adverse effects in 5 children (24%). No
child had any overt symptoms or signs of adrenal
insufficiency. One child who was on long-term alternate
day prednisolone and 800 mcg of budesonide per day
underwent formal investigation with a standard synacthen
test and this was normal.4. Discussion
This paper describes our clinical experience with a new
antifungal agent, voriconazole, in children with cystic
fibrosis. Over an 18 month period, 13 children received
voriconazole for acute ABPA and 8 were treated for a
clinical deterioration when A. fumigatus was thought to be a
contributing factor. The most interesting finding was the
apparent therapeutic effect of voriconazole in 2 children
with ABPA without the use of oral corticosteroids.
The main limitation of this study is that it is an
uncontrolled, open label, retrospective review. We decided
it would be impossible to select suitable controls from the
same or previous time periods. Managing a child with CF
and ABPA, particularly with oral corticosteroids requires an
individualised treatment regimen, and such children are not
easily compared on simple clinical parameters. We have
presented all children treated with voriconazole independent
of length of therapy. It is therefore a mixed group, especially
as it includes patients with and without ABPA. In addition,
clinical and serological parameters at the two time points
recorded do not solely reflect the effect of voriconazole
therapy. It should also be acknowledged that spontaneous
resolution of ABPA may occur, although the chronicity of
the illness in the two children we describe makes this
unlikely, and their response to voriconazole alone is
suggestive evidence of its efficacy. There did not appear
to be any benefit in those children without ABPA.
Several case series have reported the use of itraconazole
as an antifungal in the therapy of ABPA. In a retrospective
review of 21 CF patients aged 8–30 years with ABPA over
a 5 year period, 12 patients received itraconazole as
monotherapy and 9 patients received the drug in conjunction
with oral corticosteroids [7]. Itraconazole was used in high
doses (up to 600 mg per day) and for long periods (median
33 months, from 6 to 60 months). There appeared to be
some reduction in culture of A. fumigatus and improvement
in immunological status over this time period. In a separateretrospective series of 16 CF patients aged 10–44 years
with ABPA who had received prednisolone, 12 had been
also been given itraconazole, and these were compared to
the other 4 patients [8]. Patients given itraconazole received
a lower dose of oral steroids and had a reduction in the
number of acute exacerbations. Itraconazole has been
studied in 2 randomised double-blind placebo controlled
trials as therapy for ABPA, although both have been in
adults with asthma and stable ABPA, and have not included
patients with CF. In patients dependent on at least 10 mg per
day of prednisolone, itraconazole over a 16 week period was
associated with greater response rate in terms of steroid
reduction, decrease in total IgE and improvement in
pulmonary function or infiltrates compared to placebo [9].
In the second trial, again over 16 weeks and involving
patients of whom the majority were not on oral cortico-
steroids, itraconazole therapy led to a greater decrease in
sputum inflammatory markers and serum IgE compared to
placebo [10]. It is however unclear whether antifungal
therapy is beneficial in A. fumigatus infection in the absence
of ABPA or invasive disease.
Itraconazole has the disadvantage of limited oral bio-
availability, and this is particularly true for the capsule form,
requiring an acidic environment for dissolution which is
inhibited by antacid therapies [4]. The liquid formulation is
better absorbed but is unpalatable. A pharmacokinetic study
of the liquid formulation administered to 17 CF patients
over 14 days showed marked inter-subject variability, with
none of the 5 subjects under 16 years of age achieving the
recommended trough steady-state concentration [12]. Our
current practice is not to monitor serum itraconazole levels,
and this was not performed in any of the children in this
series. In contrast voriconazole has a high oral bioavail-
ability exceeding 90%, and absorption is not affected by
gastric pH [11]. The oral bioavailability may be lower in ill
patients however, and some centres are determining
voriconazole levels to ensure adequate blood concentra-
tions. It has in vitro activity against A. fumigatus which has
been found to be superior to or equivalent to itraconazole
[13,14]. The mechanisms of action are similar, inhibiting
cytochrome P450-dependent 14a-sterol demethylation, a
step required for fungal cell membrane synthesis.
Voriconazole is approved for the treatment of invasive
aspergillosis, a serious complication in immunocompro-
mised patients. In a large, open, randomised trial in invasive
aspergillosis, patients treated with voriconazole had a
greater rate of survival than those given intravenous
amphotericin B [15]. Its use in invasive fungal infections
in immunocompromised children has also been described
[16]. A single case report has documented its success in
treating an adult patient with CF and invasive aspergillosis
and aspergilloma, refractory to itraconazole and amphoter-
icin B [17].
Voriconazole appears to be generally well tolerated, but
a transient disturbance in vision has been reported to occur
in up to 30% of patients [11]. Skin reactions (rash or
T. Hilliard et al. / Journal of Cystic Fibrosis 4 (2005) 215–220220photosensitivity) are the next most common adverse effect
(reported in up to 15% of patients), and elevations in hepatic
enzymes have been reported in up to 10% of patients
[11,15,16]. No child in our series reported visual problems,
but 3 children (14%) had a skin reaction. Only one child,
with pre-existing liver disease, had an alteration in hepatic
enzymes. Like other azoles, there is a significant potential
for drug interactions due to its hepatic metabolism by
CYP450 isoenzymes [11]. Itraconazole has been found to be
associated with adrenal suppression when used alongside
inhaled corticosteroids in CF [18–20]. Formal testing of the
pituitary–adrenal axis in one child in our series was normal,
however, in the absence of complete data on adrenal
function, caution in the concomitant use of voriconazole
and corticosteroids is advisable. Itraconazole has also been
found to increase the plasma concentration of methylpred-
nisolone, but not of prednisolone, and it is currently not
clear if voriconazole has similar effects [21]. Similarly, we
do not have any data on serum drug levels, which may or
may not have been abnormally high in those children
experiencing adverse effects.
Finally, voriconazole is expensive. One month of oral
therapy of 200 mg twice per day costs approximately
C2700 ($3600) [22]. This compares to approximatelyC85
($110) for comparable treatment with itraconazole. There-
fore, with the increased cost of voriconazole and its
potential for adverse effects and drug interactions, the
decision to start this therapy in CF needs to be made very
carefully. However, the additional expense may be worth-
while if oral corticosteroids can be avoided or the dose
minimised.
In conclusion, we report apparent benefit from the use of
voriconazole in 2 children with CF and ABPA who
demonstrated clear clinical and serological improvement
without the use of further oral corticosteroids. We suggest
that voriconazole should be considered as an alternative
antifungal in ABPA, particularly when oral corticosteroids
are deemed unsuitable.References
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